KalVista Pharmaceuticals (KALV) Receivables Refunds: 2017-2024
Historic Receivables Refunds for KalVista Pharmaceuticals (KALV) over the last 5 years, with Dec 2024 value amounting to $11.4 million.
- KalVista Pharmaceuticals' Receivables Refunds was N/A to $11.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.4 million, marking a year-over-year change of. This contributed to the annual value of $8.4 million for FY2024, which is N/A change from last year.
- Latest data reveals that KalVista Pharmaceuticals reported Receivables Refunds of $11.4 million as of Q4 2024, which was up 3.02% from $11.1 million recorded in Q4 2024.
- In the past 5 years, KalVista Pharmaceuticals' Receivables Refunds registered a high of $23.0 million during Q1 2024, and its lowest value of $7.6 million during Q1 2021.
- Over the past 2 years, KalVista Pharmaceuticals' median Receivables Refunds value was $11.4 million (recorded in 2024), while the average stood at $14.7 million.
- As far as peak fluctuations go, KalVista Pharmaceuticals' Receivables Refunds surged by 65.03% in 2020, and later slumped by 48.73% in 2021.
- Over the past 4 years, KalVista Pharmaceuticals' Receivables Refunds (Quarterly) stood at $14.7 million in 2020, then crashed by 48.73% to $7.6 million in 2021, then reached $20.0 million in 2023, then tumbled by 44.52% to $11.4 million in 2024.
- Its last three reported values are $11.4 million in Q4 2024, $11.1 million for Q4 2024, and $9.9 million during Q3 2024.